Hologic, Inc. (HOLX) Analysts See $0.49 EPS

January 22, 2018 - By Dolores Ford

 Hologic, Inc. (HOLX) Analysts See $0.49 EPS
Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.50, from 1.38 in 2017Q2. It is negative, as 75 investors sold Hologic, Inc. shares while 145 reduced holdings. 64 funds opened positions while 129 raised stakes. 265.54 million shares or 0.74% less from 267.53 million shares in 2017Q2 were reported.
Quantbot Tech Lp reported 288,140 shares. Chevy Chase Trust Incorporated stated it has 244,620 shares or 0.04% of all its holdings. Marsico Capital Ltd Com has 0.08% invested in Hologic, Inc. (NASDAQ:HOLX) for 52,860 shares. Thompson Management reported 0.54% in Hologic, Inc. (NASDAQ:HOLX). Blair William & Il has 0% invested in Hologic, Inc. (NASDAQ:HOLX) for 16,474 shares. State Of Wisconsin Investment Board owns 442,751 shares. Salem Investment Counselors Inc, a North Carolina-based fund reported 208 shares. Putnam Invs Ltd Co reported 80,313 shares. Trexquant Investment L P holds 0.46% of its portfolio in Hologic, Inc. (NASDAQ:HOLX) for 49,267 shares. Northpointe Cap Ltd Liability Corporation holds 0.3% in Hologic, Inc. (NASDAQ:HOLX) or 77,166 shares. Johnson Gp accumulated 100 shares. Boston Family Office Limited Co holds 0.21% or 51,145 shares. Rhumbline Advisers holds 574,802 shares or 0.05% of its portfolio. Cornerstone Cap Hldg Limited Liability Com, New York-based fund reported 47,664 shares. Swiss Bank stated it has 0.05% in Hologic, Inc. (NASDAQ:HOLX).

Since August 3, 2017, it had 0 insider purchases, and 4 sales for $1.18 million activity. ULLIAN ELAINE had sold 6,902 shares worth $276,908 on Thursday, August 3.

Analysts expect Hologic, Inc. (NASDAQ:HOLX) to report $0.49 EPS on February, 7.They anticipate $0.03 EPS change or 5.77 % from last quarter’s $0.52 EPS. HOLX’s profit would be $135.08M giving it 22.17 P/E if the $0.49 EPS is correct. After having $0.50 EPS previously, Hologic, Inc.’s analysts see -2.00 % EPS growth. The stock decreased 0.89% or $0.39 during the last trading session, reaching $43.46. About 4.36 million shares traded or 52.23% up from the average. Hologic, Inc. (NASDAQ:HOLX) has risen 29.21% since January 22, 2017 and is uptrending. It has outperformed by 12.51% the S&P500.

Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage

Among 17 analysts covering Hologic (NASDAQ:HOLX), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Hologic has $5300 highest and $40 lowest target. $48.67’s average target is 11.99% above currents $43.46 stock price. Hologic had 49 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by Argus Research with “Buy” on Monday, August 3. Barclays Capital upgraded it to “Overweight” rating and $44 target in Friday, September 23 report. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, June 15. Bank of America upgraded the shares of HOLX in report on Thursday, January 4 to “Buy” rating. The firm has “Buy” rating by Jefferies given on Tuesday, June 27. The stock of Hologic, Inc. (NASDAQ:HOLX) has “Buy” rating given on Wednesday, December 20 by Cowen & Co. On Thursday, August 3 the stock rating was maintained by Barclays Capital with “Overweight”. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, January 3. The company was downgraded on Wednesday, October 21 by Craig Hallum. RBC Capital Markets maintained Hologic, Inc. (NASDAQ:HOLX) rating on Friday, September 22. RBC Capital Markets has “Hold” rating and $42.0 target.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company has market cap of $11.98 billion. It operates through four divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It has a 16.46 P/E ratio. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test.

Another recent and important Hologic, Inc. (NASDAQ:HOLX) news was published by Prnewswire.com which published an article titled: “Hologic Announces Pricing of Offering of $1 Billion of Senior Notes” on January 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: